Moderna: unveils advances at its R&D Day

(CercleFinance.com) - At its R&D Day, Moderna highlighted advances in its mRNA pipeline and a revised financial framework.
NB: pmt -10.3%.

Moderna says it has five respiratory vaccines with positive Phase 3 results, and plans to submit three of them for approval this year. The company is also focusing on five non-respiratory products in pivotal studies by 2027.

From 2027 onwards, the laboratory plans to reduce its R&D expenditure by $1.1bn p.a. to concentrate on commercialization and new product development.

It aims to obtain 10 product approvals over the next three years.


Copyright (c) 2024 CercleFinance.com. All rights reserved.